Rhythm Pharmaceuticals (RYTM)

Rhythm Pharmaceuticals Limited • Rhythm Securities Corp. • Rhythm Pharmaceuticals Netherlands, B.V. • Rhythm Pharmaceuticals UK Limited • Rhythm Pharmaceuticals France SAS • Rhythm Pharmaceuticals Italy S.r.L. • Rhythm Pharmaceuticals Canada Inc. • Rhythm Pharmaceuticals Germany GmbH • Xinvento, B.V. • Rhythm Pharmaceuticals Spain S.L. ...

RYTM stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$132.17

Low target

$110.00

High target

$145.00

Latest filings (excl ownership)

View all

8-K

Regulation FD Disclosure

11 Dec 25

8-K

Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity

4 Nov 25

Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update

5 Aug 25

Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update

Prospectus supplement for primary offering

10 Jul 25

424B5

Prospectus supplement for primary offering

9 Jul 25

8-K

Regulation FD Disclosure

9 Jul 25

Transcripts

View all

RYTM

Earnings call transcript

2025 Q3

4 Nov 25

RYTM

Earnings call transcript

2025 Q2

5 Aug 25

RYTM

Earnings call transcript

2024 Q4

26 Feb 25

RYTM

Earnings call transcript

2024 Q3

5 Nov 24

RYTM

Earnings call transcript

2024 Q2

6 Aug 24

RYTM

Earnings call transcript

2024 Q1

7 May 24

RYTM

Earnings call transcript

2023 Q4

22 Feb 24

RYTM

Earnings call transcript

2023 Q3

7 Nov 23

RYTM

Earnings call transcript

2023 Q2

1 Aug 23

RYTM

Earnings call transcript

2023 Q2

1 Aug 23

Latest ownership filings

View all

Pamela J. Cramer

24 Nov 25

144

Notice of proposed sale of securities

20 Nov 25

SCHEDULE 13G/A

Beneficial ownership report (amended)

Notice of proposed sale of securities

10 Nov 25

144

Notice of proposed sale of securities

Notice of proposed sale of securities

30 Oct 25

SCHEDULE 13G/A

Beneficial ownership report (amended)

30 Oct 25

Financial summary

Financial statements Chart RYTM financial data

Quarter (USD)	Sep 25	Jun 25	Mar 25	Dec 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	52.75 mm	52.75 mm	52.75 mm	52.75 mm	52.75 mm	52.75 mm
Cash burn (monthly)	27.79 mm	(no burn)	17.60 mm	15.99 mm	8.87 mm	9.09 mm
Cash used (since last report)	67.17 mm	n/a	42.54 mm	38.65 mm	21.45 mm	21.98 mm
Cash remaining	-14.42 mm	n/a	10.21 mm	14.10 mm	31.30 mm	30.77 mm
Runway (months of cash)	-0.5	n/a	0.6	0.9	3.5	3.4

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

RYTM institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	208	183	+13.7%
Opened positions	53	32	+65.6%
Closed positions	28	19	+47.4%
Increased positions	64	59	+8.5%
Reduced positions	53	55	-3.6%

13F shares	Current	Prev Q	Change
Total value	3.53 tn	3.46 tn	+1.9%
Total shares	71.44 mm	74.25 mm	-3.8%
Total puts	26.60 k	78.60 k	-66.2%
Total calls	444.50 k	833.60 k	-46.7%
Total put/call ratio	0.1	0.1	-36.5%

Largest owners	Shares	Value	Change
BlackRock	6.95 mm	$389.10 bn	+0.9%
Primecap Management	6.57 mm	$367.86 bn	-8.9%
Ra Capital Management	6.08 mm	$340.61 bn	0.0%
Baker Bros. Advisors	6.08 mm	$340.60 bn	-4.9%
Perceptive Advisors	3.68 mm	$206.03 bn	+3.4%
Vanguard	3.44 mm	$192.72 bn	-0.2%
New Enterprise Associates 13	2.91 mm	$70.83 mm	0.0%
NEA Management	2.91 mm	$162.90 bn	0.0%
Frazier Life Sciences Management	1.87 mm	$104.67 bn	-22.6%
Flynn James E	1.87 mm	$18.64 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
GS The Goldman Sachs Group, Inc.	1.81 mm	-2.07 mm	-53.3%
Healthcare Of Ontario Pension Plan Trust Fund	0.00	-1.11 mm	EXIT
Commodore Capital	0.00	-650.00 k	EXIT
Primecap Management	6.57 mm	-645.72 k	-8.9%
JHG Janus Henderson	1.22 mm	+621.43 k	+103.9%
Frazier Life Sciences Management	1.87 mm	-547.14 k	-22.6%
NA.R National Bank of Canada	0.00	-341.51 k	EXIT
Baker Bros. Advisors	6.08 mm	-314.12 k	-4.9%
Marshall Wace	692.80 k	+286.19 k	+70.4%
Norges Bank	205.65 k	+205.65 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

RYTM insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
20 Nov 25	Pamela J. Cramer	Common Stock	Sell	Dispose S	No	Yes	105	3,350	351.75 k	20,814
20 Nov 25	Pamela J. Cramer	Common Stock	Option exercise	Acquire M	No	No	27.35	3,350	91.62 k	24,164
20 Nov 25	Pamela J. Cramer	Stock Options Common Stock	Option exercise	Dispose M	No	No	27.35	3,350	91.62 k	11,725
10 Nov 25	Pamela J. Cramer	Common Stock	Sell	Dispose S	No	Yes	100	3,515	351.50 k	20,814
10 Nov 25	Pamela J. Cramer	Common Stock	Option exercise	Acquire M	No	No	6.8	3,515	23.90 k	24,329
10 Nov 25	Pamela J. Cramer	Stock Options Common Stock	Option exercise	Dispose M	No	No	6.8	3,515	23.90 k	3,520
7 Nov 25	Pamela J. Cramer	Common Stock	Sell	Dispose S	No	Yes	98.8231	19,351	1.91 mm	20,814
7 Nov 25	Pamela J. Cramer	Common Stock	Option exercise	Acquire M	No	No	6.8	10,546	71.71 k	40,165
7 Nov 25	Pamela J. Cramer	Common Stock	Option exercise	Acquire M	No	No	19.02	8,805	167.47 k	29,619
7 Nov 25	Pamela J. Cramer	Stock Options Common Stock	Option exercise	Dispose M	No	No	6.8	10,546	71.71 k	7,035